ATE475674T1 - Angiogenische und immunologische verwendungen von anti-cd160 spezifischen stoffen, erhältlich vom monoklonalen antiköper cl1-r2 - Google Patents

Angiogenische und immunologische verwendungen von anti-cd160 spezifischen stoffen, erhältlich vom monoklonalen antiköper cl1-r2

Info

Publication number
ATE475674T1
ATE475674T1 AT05789182T AT05789182T ATE475674T1 AT E475674 T1 ATE475674 T1 AT E475674T1 AT 05789182 T AT05789182 T AT 05789182T AT 05789182 T AT05789182 T AT 05789182T AT E475674 T1 ATE475674 T1 AT E475674T1
Authority
AT
Austria
Prior art keywords
monoclonal antibody
angiogenic
specific substances
substances available
immunological
Prior art date
Application number
AT05789182T
Other languages
English (en)
Inventor
Armand Bensussan
Laurence Boumsell
Bouteiller Philippe Le
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE475674T1 publication Critical patent/ATE475674T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2836—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD106
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
AT05789182T 2004-08-09 2005-08-09 Angiogenische und immunologische verwendungen von anti-cd160 spezifischen stoffen, erhältlich vom monoklonalen antiköper cl1-r2 ATE475674T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04292015A EP1626059A1 (de) 2004-08-09 2004-08-09 Angiogenische und immunologische Verwendungen von anti-CD160 spezifischen Stoffen, erhältlich vom monoklonalen Antiköper CL1-R2
PCT/EP2005/009231 WO2006015886A1 (en) 2004-08-09 2005-08-09 Angiogenic and immunologic applications of anti-cd160 specific compounds obtainable from mab cl1-r2

Publications (1)

Publication Number Publication Date
ATE475674T1 true ATE475674T1 (de) 2010-08-15

Family

ID=34931332

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05789182T ATE475674T1 (de) 2004-08-09 2005-08-09 Angiogenische und immunologische verwendungen von anti-cd160 spezifischen stoffen, erhältlich vom monoklonalen antiköper cl1-r2

Country Status (10)

Country Link
US (4) US20090317401A1 (de)
EP (2) EP1626059A1 (de)
JP (1) JP5162239B2 (de)
AT (1) ATE475674T1 (de)
CA (1) CA2576627C (de)
DE (1) DE602005022589D1 (de)
DK (1) DK1776387T3 (de)
ES (1) ES2349015T3 (de)
PL (1) PL1776387T3 (de)
WO (1) WO2006015886A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE031989T2 (en) 2005-10-04 2017-08-28 Soligenix Inc New peptides for the treatment and prevention of immune-related disorders, including treatment and prevention of infection by modulation of natural immunity
EP1880729A1 (de) * 2006-07-20 2008-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Verwendung des löslichen CD160 zur Unterdrückung der Immunität
EP2210903A1 (de) * 2009-01-21 2010-07-28 Monoclonal Antibodies Therapeutics Monoklonale Antikörper gegen CD160 und Anwendungen davon
PL2575881T3 (pl) * 2010-05-28 2018-06-29 Inserm - Institut National De La Santé Et De La Recherche Médicale Przeciwciała swoiste wobec CD160 do leczenia zaburzeń oczu związanych z angiogenezą
US9982023B2 (en) * 2011-11-15 2018-05-29 Sanford-Burnham Medical Research Institute Compositions and methods for treating autoimmune and inflammatory disorders
WO2018077926A1 (en) 2016-10-25 2018-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Monoclonal antibodies binding to the cd160 transmembrane isoform
FR3061716B1 (fr) 2017-01-06 2019-05-17 Elsalys Biotech Nouveaux composes ciblant le cd160 humain
JP2022514702A (ja) 2018-12-21 2022-02-14 オーエスイー・イミュノセラピューティクス 二機能性抗ｐｄ－１／ｉｌ－７分子
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
AU2020406083A1 (en) 2019-12-17 2022-06-16 Ose Immunotherapeutics Bifunctional molecules comprising an IL-7 variant
WO2022013256A1 (en) 2020-07-15 2022-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd160 as a biomarker in acute myeloid leukemia
CA3187272A1 (en) 2020-10-08 2022-04-14 Thorsten Ross Trispecific binders
GB202103706D0 (en) * 2021-03-17 2021-04-28 Ucl Business Ltd CD160 binding domain
EP4320156A1 (de) 2021-04-09 2024-02-14 Ose Immunotherapeutics Gerüst für bifunctioanlmoleküle mit pd-1- oder cd28- und sirp-bindenden domänen
IL307419A (en) 2021-04-09 2023-12-01 Ose Immunotherapeutics A new scaffold for bifunctional molecules with improved properties
CA3216098A1 (en) 2021-07-30 2023-02-02 Uwe Reusch Duplexbodies
WO2023170207A1 (en) 2022-03-09 2023-09-14 Alderaan Biotechnology Anti-cd160 transmembrane isoform antibodies
WO2023222886A1 (en) 2022-05-20 2023-11-23 Depth Charge Ltd Antibody-cytokine fusion proteins
WO2024028386A1 (en) 2022-08-02 2024-02-08 Ose Immunotherapeutics Multifunctional molecule directed against cd28
WO2024056862A1 (en) 2022-09-15 2024-03-21 Avidicure Ip B.V. Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69430846T2 (de) * 1993-08-27 2003-01-16 Dana Farber Cancer Inst Inc Für natürliche killerzellen spezifische antigene und sie identifizierende antikörper
WO1998021240A1 (en) * 1996-11-12 1998-05-22 Dana-Farber Cancer Institute Recombinant by55 and nucleic acids encoding same
WO2001036630A2 (en) * 1999-11-15 2001-05-25 Innate Pharma S.A.S. Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same
FR2828403B1 (fr) * 2001-08-07 2003-10-17 Abtech Utilisation de molecules solubles hla de classe 1 pour la preparation de compositions pharmaceutiques utiles pour inhiber l'angiogenese
US20050032725A1 (en) * 2002-10-09 2005-02-10 Toerrx, Inc. Molecules preferentially associated with effector T cells or regulatory T cells and methods of their use

Also Published As

Publication number Publication date
US20090317401A1 (en) 2009-12-24
CA2576627A1 (en) 2006-02-16
US20150004170A1 (en) 2015-01-01
US20140120110A1 (en) 2014-05-01
US8444978B2 (en) 2013-05-21
DE602005022589D1 (de) 2010-09-09
JP2008517873A (ja) 2008-05-29
EP1776387B1 (de) 2010-07-28
DK1776387T3 (da) 2010-11-22
EP1626059A1 (de) 2006-02-15
CA2576627C (en) 2014-02-18
US20120003224A1 (en) 2012-01-05
EP1776387A1 (de) 2007-04-25
PL1776387T3 (pl) 2011-01-31
ES2349015T3 (es) 2010-12-21
JP5162239B2 (ja) 2013-03-13
WO2006015886A1 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
ATE475674T1 (de) Angiogenische und immunologische verwendungen von anti-cd160 spezifischen stoffen, erhältlich vom monoklonalen antiköper cl1-r2
DK1869085T3 (da) Hidtil ukendt anti-PLGF-antistof
CY1111542T1 (el) Αντισωματα εξουδετερωσης του rsv υπερυψηλης συγγενειας
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
EP1461081A4 (de) Anti-cd45rb-antikörper zur verwendung bei der behandlung von autoimmunkrankheiten und transplantatabstossung
ATE389454T1 (de) Assayvorrichtung und verfahren mit gesteuertem fluss
ATE464374T1 (de) Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen
DE60334453D1 (de) Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
FR2794865B1 (fr) Methode de detection precoce des flavivirus et ses applications
NO20072721L (no) Polypeptides that bind BR3 and uses thereof
DK1706424T3 (da) FC-region varianter
DE60135498D1 (de) Produktion von ganzen Antikörpern in prokaryontischen Zellen
NO20073981L (no) Criptobindende molekyler
UA92504C2 (en) Anti-myostatin monoclonal antibody
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения
ATE414106T1 (de) Pegylierte single-domain-antikörper (dab)
DE60232660D1 (de) Humane dr4-antikörper und deren anwendungen
DK1771732T3 (da) Taxol-immunassay
ATE526399T1 (de) Neue biologische einheiten und deren verwendung
DE60321041D1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
RS50671B (sr) Kristalisan polietilen tereftalat, koji sadrži silicijum, i postupak za njegovo dobijanje
DE602004016499D1 (de) Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung
ATE458006T1 (de) Humaner monoklonaler antikörper spezifisch für lipopolysacchariden (lps) des serotyps iats o6 von pseudomonas aeruginosa
ATE494307T1 (de) Neoplasma-spezifische antikörper und deren verwendungen
ATE470478T1 (de) An ovarialkrebs beteiligtes protein